Effects of dapagliflozin on body composition and its relation to hemodynamics in heart failure with preserved ejection fraction: the CAMEO-DAPA randomized clinical trial
Event:
ESC Congress 2024
Topic:
Pharmacotherapy
Session:
Further Insights into SGLT2i treatment for heart failure
The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes
Event:
ESC Congress 2022
Topic:
Anticoagulants
Session:
Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities